21.06.2013 • News

Statements: Market Trends

Company

Krahn Chemie

Mühlenhagen 35
20539 Hamburg
Germany

Company contact

I am interested in:

an offer
a callback
detailed information

Your request

salutation first name last name

country phone email

Please note our data protection information for the contact form.

Virtual Event

Outsourced Biomanufacturing

Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation

Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Top-Feature

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

most read

News • Bioprocessing

Merck Acquires Chromatography Business from JSR Life Sciences

Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.

News • Chemistry

Jens Birgersson Becomes New Brenntag CEO

Jens Birgersson becomes new Brenntag CEO

News • Chemistry

BASF Sells Majority Stake in Coatings Business

BASF sells a majority stake in its coatings business to the investor Carlyle.

News • Chemistry

Orion Announced Plans to Shut Down Carbon Black Plants

Carbon black manufacturer Orion Engineered Carbons plans to rationalize production lines in North and South America and EMEA.

Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring

Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.